Trial Profile
Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Apabetalone (Primary)
- Indications Atherosclerosis; Coronary artery disease
- Focus Biomarker; Therapeutic Use
- Acronyms ASSERT
- Sponsors Resverlogix Corporation
- 15 Nov 2017 Results of ASSERT, SUSTAIN and ASSURE trials assessing presented at the 90th Annual Scientific Sessions of the American Heart Association.
- 12 Oct 2017 Results of a pooled analysis from ASSERT, ASSURE, SUSTAIN trials (n = 798) published in the American Journal of Cardiovascular Drugs
- 16 Nov 2016 Results of post hoc analysis of phase IIb ASSERT and ASSURE trials (n=51), presented at the 89th Annual Scientific Sessions of the American Heart Association